NO activity in familial combined hyperlipidemia: Potential role of cholesterol remnants

Cardiovascular Research

Volumn 36, Issue 3, 1997, Pages 445-452

  Stroes, Erik ^a   De Bruin, Tjerk ^b   De Valk, Harold ^b   Erkelens, Willem ^b   Banga, Jan Dirk ^b   Van Rijn, Herman ^b   Koomans, Hein ^a   Rabelink, Ton ^a  

^a Univ Hosp U   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Endothelium; Familial combined hyperlipidemia; Forearm; Human; Lipid lowering therapy; Nitric oxide

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SEROTONIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FAMILIAL HYPERLIPEMIA; FOREARM BLOOD FLOW; HEMODYNAMIC PARAMETERS; HUMAN; MALE; PRIORITY JOURNAL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; ANTILIPEMIC AGENTS; ARGININE; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FOREARM; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; MALE; MIDDLE AGED; NITRIC OXIDE; NITROPRUSSIDE; REGIONAL BLOOD FLOW; SEROTONIN; SIMVASTATIN; VASODILATION;

EID: 0031458360     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00199-5     Document Type: Article

References (42)

1. Grundy S.M., Chait A., Brunzell J.D. Familial combined hyperlipdemia workshop. Arteriosclerosis. 7:1987;203-207.
2. Venkatesan S., Cullen P., Pacy P., Halliday D., Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arteriosclerosis Thrombosis. 13:1993;1110-1118.
3. Cabezas M.C., de Bruin T.W.A., Jansen H., Kock L.A.W., Kortlandt W., Erkelens D.W. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arteriosclerosis and Thrombosis. 13:1993;804-814.
4. Cabezas M.C., de Bruin T.W.A., de Valk H.W., Shoulders C.C., Jansen H., Erkelens D.W. Impaired fatty acid metabolism in familial combined hyperlipidemia. J Clin Invest. 92:1993;160-168.
5. Goldstein J.L., Schrott H.G., Hazzard W., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease: II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:1973;1544-1568.
6. Brunzell J.D., Schrott H.G., Matulsky A.G., Bierman E.L. Myocardial infarction in the familial forms of hypertriglyceridaemia. Metabolism. 25:1976;313-320.
7. Gauthier T.W., Scalia R., Murohara T., Guo J.P., Lefer A.M. Nitric oxide protects against leucocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Throm. 15:1995;1652-1659.
8. Quyyumi A.A., Dakak N., Mulcahy D., Andrews N.P., Husain S., Panza J.A., Cannon R.O. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol. 29:1997;308-317.
9. Dzau V. Pathobiology of atherosclerosis and plaque complications. Am Heart J. 128:1994;1300-1304.
10. Stroes E.S.G., Koomans H.A., de Bruin T.W.A., Rabelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 346:1995;467-471.
11. Chowienczyk P.J., Watts G.F., Cockroft J.R., Ritter J.M. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolaemia. Lancet. 340:1992;1430-1432.
12. Dallinga-Thie G.M., Bu X.D., van Linde Sibenius Trip M., Rotter J.I., Lusis A.J., de Bruin T.W.A. Apolipoprotein AI-CIII-AiV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res. 37:1996;136-147.
13. Bruning T.A., Zwieten P.A., van Blauw G.J., Chang P.C. No functional involvement of 5-hydroxytryptamine 1a receptors in nitric oxide dependent dilation caused by serotonin in the human forearm vascular bed. J Cardiovasc Pharmacol. 24:1994;454-461.
14. Van Tol A., Jansen E.J.H.M., Koomans H.A., Joles J.A. Characterization of hyperlipoproteinemia in Nagase analbuminemic rats: effects of pravastatin, an HMG-CoA reductase inhibitor, on plamsa apolipoproteins, lipoprotein profile and lecithin: cholesteryl acyltransferase activity. J Lipid Res. 32:1991;1719-1728.
15. Benjamin N., Calver A., Collier J., Robinson B., Vallence P., Webb D. Measuring forearm blood flow and interpreting the responses to Drugs and Mediators. Hypertension. 25:1995;918-923.
16. Loscalzo J., Welch G. Nitric oxide and its role in the cardiovascular system. Progress in Cardiovascular disease. 38(2):1995;87-104.
17. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
18. Jacobs M.C., Lenders W.M., Kapma J.A., Smits P., Thien T. Effect of chronic smoking on endothelium-dependent vascular relaxation in humans. Clin Sci. 85:1993;51-55.
19. Fleischauer F.J., Yan W.D., Fischell T.A. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 21:1993;982-989.
20. Chin J.P.F., Dart A.M. Therapeutic restoration of endothelial function in hypercholesterolaemic subjects. Effects of fish oils. Clin Exp Pharmacol Physiol. 21:1994;749-756.
21. Eichstadt H.W., Eskotter H., Hoffmann I., Armthauer H.W., Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 76:1995;122A-125A.
22. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
23. Kameda K., Matsuzawa Y., Kubo M. Increased frequency of lipoprotein disorders similar to type III hyperlipoproeinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 51:1984;241-249.
24. Steiner G., Schwartz L., Shumak S., Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 75:1987;124-130.
25. Senti M., Nogues X., Pedro-Botet J., Rubies-Prat J., Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease: Role of intermediate density lipoproteins and apolipoprotein E phenotypes. Circulation. 85:1992;30-36.
26. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brenske J, Vranizank K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;ii:62-66.
27. Philips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:1993;2762-2770.
28. Hodis H.N., Mack W.J., Azen S.P., Alaupovic P., Pogoda J.M., LaBree L., Hemphill L.C., Kramsch P.M., Blankenhorn D.H. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49.
29. Hodis H.N., Mack W.J., Dunn M., Liu C.R., Liu C.H., Selzer R.H., Kraus R.M. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 95:1997;2022-2026.
30. Stender S., Zilversmit D.B. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits; molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis. 1:1981;28-49.
31. Van Lenten BJ. Receptor-mediated uptake of remnant lipoproteins by cholesterol-laden human monocyte-macrophages. J Biol Chem 1985;8783-8788.
32. Innerarity T.L., Arnold K.S., Weisgraber K.H., Mahley R.W. Apolipoprotein E is the determinant that mediates the receptor uptake of beta-very low density lipoproteins by mouse macrophages. Ateriosclerosis. 6:1986;114-122.
33. Grundy S.M. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol. 75:1995;45b-52b.
34. Slyper A.H. A fresh look at the remnant hypothesis. Lancet. 340:1992;289.
35. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
36. Notarbartolo A., Davi G., Averna M., Barbayallo C.M., Ganci A., Giammarresi C., La-Placa F.P., Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type Iia hypercholesterolemia. Arteriosclerosis Thromb Vasc Biol. 15:1995;247-251.
37. Luscher T.F., Boulanger C.M., Yang Z., Noll G., Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation. 87(suppl. V):1993;V36-V44.
38. Seiler C., Suter T.M., Hess O.M. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 26:1995;1615-1622.
39. Leung W.H., Lau C.P., Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
40. Pritchard K.A., Groszek L., Smalley D.M., Sessa W.C., Wu M., Villalon P., Wollin M.S., Stemerman M.B. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 77:1995;510-518.
41. Cosentino F., Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation. 91:1995;139-144.
42. Stroes E.S.G., Kastelein J.J., Cosentino F., Erkelens D.W., Wever R., Koomans H.A., Luscher T.F., Rabelink T.J. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 99:1997;41-46.